drugset
drugset / Trial / NCT00281008

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00281008 ↗

Phase 2 Completed 44 enrolled Kastle Therapeutics, LLC Ionis Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia

Timeline

Start
2006-02
Primary completion
2007-07
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject mipomersen Antisense oligonucleotide 50 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 100 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 200 mg Subcutaneous
Subject mipomersen Antisense oligonucleotide 300 mg Subcutaneous

Indications

familial hypercholesterolemia